AR and breast carcinoma: Therefore, both AR antagonists and AR agonists will likely become useful and safe options of treatment in various breast cancer subtypes particularly in combination with other agents already proved to be beneficial in treating breast cancer, but only the ongoing and future prospective clinical trials will allow us to establish which agents are the best options in every specific condition [8, 9, 13, 16, 20–22].